文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛心脑血管急症

需体外膜氧合的COVID-19患者神经系统并发症:系统评价与Meta分析

Neurologic Complications of Patients With COVID-19 Requiring Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Explor · 2023-03-27
一句话结论需静脉-静脉体外膜氧合的COVID-19患者颅内出血发生率为11%,神经系统并发症使院内死亡风险增至2.24倍,应高度警惕颅内出血。

该系统评价与Meta分析检索MEDLINE、Embase、PsycINFO、Cochrane和MedRxiv数据库至2022年3月15日,纳入54项研究共3347例需体外膜氧合的成人重症急性呼吸综合征冠状病毒2型感染患者,其中97%使用静脉-静脉体外膜氧合。静脉-静脉体外膜氧合患者颅内出血发生率为11%(95%CI 8-15%),以脑实质出血最常见(73%);缺血性卒中发生率为2%(95%CI 1-3%)。较高抗凝目标未与颅内出血频率增加相关(p=0.06)。院内死亡率为37%(95%CI 34-40%),神经系统原因居死亡原因第三位;与无神经系统并发症者相比,有神经系统并发症者死亡风险比为2.24(95%CI 1.46-3.46)。作者认为医护人员应认识到这些风险并对颅内出血保持高度怀疑。

要点

  • 需静脉-静脉体外膜氧合的COVID-19患者颅内出血发生率为11%(95%CI 8-15%),脑实质出血是最常见亚型(73%)。
  • 静脉-静脉体外膜氧合患者缺血性卒中发生率为2%(95%CI 1-3%)。
  • 较高抗凝目标与颅内出血频率增加无显著关联(p=0.06)。
  • 院内死亡率为37%(95%CI 34-40%),神经系统原因居死亡原因第三位。
  • 合并神经系统并发症者死亡风险比为2.24(95%CI 1.46-3.46),作者认为应对颅内出血保持高度怀疑。

适用人群与场景

  • 成人重症急性呼吸综合征冠状病毒2型感染需体外膜氧合的患者;纳入研究中97%的患者使用静脉-静脉体外膜氧合。
  • Meta分析仅纳入95%及以上患者使用静脉-静脉或静脉-动脉体外膜氧合的研究;静脉-动脉体外膜氧合患者因研究不足未行Meta分析。

红旗征与不能漏的情况

  • 需静脉-静脉体外膜氧合的COVID-19患者颅内出血发生率为11%(95%CI 8-15%),作者认为医护人员应对颅内出血保持高度怀疑。

研究设计与关键结果

  • 系统评价纳入54项研究共3347例患者,其中97%使用静脉-静脉体外膜氧合;颅内出血和缺血性卒中的Meta分析分别纳入18项和11项静脉-静脉体外膜氧合研究。
  • 颅内出血发生率为11%(95%CI 8-15%),脑实质出血为最常见亚型(73%);缺血性卒中发生率为2%(95%CI 1-3%)。
  • 较高抗凝目标与颅内出血频率增加无显著关联(p=0.06)。
  • 院内死亡率为37%(95%CI 34-40%),神经系统原因居死亡原因第三位。
  • 合并神经系统并发症的静脉-静脉体外膜氧合COVID-19患者与无神经系统并发症者相比,死亡风险比为2.24(95%CI 1.46-3.46)。
  • 静脉-动脉体外膜氧合COVID-19患者因研究不足未行Meta分析。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(随机效应模型),检索MEDLINE、Embase、PsycINFO、Cochrane和MedRxiv数据库自建库至2022年3月15日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,医护人员应认识到需静脉-静脉体外膜氧合的COVID-19患者颅内出血和神经系统并发症风险升高,并对颅内出血保持高度怀疑。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: In COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO), our primary objective was to determine the frequency of intracranial hemorrhage (ICH). Secondary objectives were to estimate the frequency of ischemic stroke, to explore association between higher anticoagulation targets and ICH, and to estimate the association between neurologic complications and in-hospital mortality.

DATA SOURCES: We searched MEDLINE, Embase, PsycINFO, Cochrane, and MedRxiv databases from inception to March 15, 2022.

STUDY SELECTION: We identified studies that described acute neurological complications in adult patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection requiring ECMO.

DATA EXTRACTION: Two authors independently performed study selection and data extraction. Studies with 95% or more of its patients on venovenous or venoarterial ECMO were pooled for meta-analysis, which was calculated using a random-effects model.

DATA SYNTHESIS: Fifty-four studies (n = 3,347) were included in the systematic review. Venovenous ECMO was used in 97% of patients. Meta-analysis of ICH and ischemic stroke on venovenous ECMO included 18 and 11 studies, respectively. The frequency of ICH was 11% (95% CI, 8-15%), with intraparenchymal hemorrhage being the most common subtype (73%), while the frequency of ischemic strokes was 2% (95% CI, 1-3%). Higher anticoagulation targets were not associated with increased frequency of ICH (p = 0.06). In-hospital mortality was 37% (95% CI, 34-40%) and neurologic causes ranked as the third most common cause of death. The risk ratio of mortality in COVID-19 patients with neurologic complications on venovenous ECMO compared with patients without neurologic complications was 2.24 (95% CI, 1.46-3.46). There were insufficient studies for meta-analysis of COVID-19 patients on venoarterial ECMO.

CONCLUSIONS: COVID-19 patients requiring venovenous ECMO have a high frequency of ICH, and the development of neurologic complications more than doubled the risk of death. Healthcare providers should be aware of these increased risks and maintain a high index of suspicion for ICH.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Li CMF, Densy Deng X, Ma YF, et al. Neurologic Complications of Patients With COVID-19 Requiring Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. Crit Care Explor. 2023. PMID: 36998530. doi:10.1097/CCE.0000000000000887

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。